Commentary

Risk-reducing salpingectomy during surgery for benign indications


 

References

Ovarian cancer remains the most deadly gynecologic malignancy. Efforts to find effective screening methods have not yet delivered. Pathologic data confirms that over half of “ovarian” cancers are actually of tubal origin, and we should consider risk-reducing salpingectomy in the low-risk population. The Society of Gynecologic Oncology in their November 2013 Clinical Practice Statement stated, “For women at average risk of ovarian cancer, risk-reducing salpingectomy should also be discussed and considered with patients at the time of abdominal or pelvic surgery, hysterectomy or in lieu of tubal ligation [once childbearing is complete].”

Dr. Pierce is a third-year resident in the department of obstetrics and gynecology at the University of North Carolina at Chapel Hill. Dr. Clarke-Pearson is the chair and the Robert A. Ross Distinguished Professor of Obstetrics and Gynecology, and a professor in the division of gynecologic oncology at the university. Dr. Pierce and Dr. Clarke-Pearson said that they had no relevant financial disclosures.

Pages

Recommended Reading

Paradigm shift: Prophylactic salpingectomy for ovarian cancer risk reduction
MDedge Hematology and Oncology
Widespread BRCA1/BRCA2 screening recommendation draws praise, fire
MDedge Hematology and Oncology
Ovarian cancer often arises from precursor endometriosis
MDedge Hematology and Oncology
AUDIO: Hope Rugo reviews pivotal breast cancer trials at ESMO
MDedge Hematology and Oncology
Biomarker predicts bone loss in premenopausal breast cancer patients
MDedge Hematology and Oncology
CLEOPATRA sets new standard treatment paradigm for metastatic breast cancer
MDedge Hematology and Oncology
Genetic screen not worth cost for node-negative breast cancer patients
MDedge Hematology and Oncology
20-year follow-up supports adjuvant radiotherapy for DCIS
MDedge Hematology and Oncology
IBD, especially Crohn’s disease, linked to cervical neoplasia
MDedge Hematology and Oncology
Should ductal carcinoma in situ be treated?
MDedge Hematology and Oncology